blincyto
amgen europe b.v. - blinatumomab - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
improvac
zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - sigalaste immunoloogilised omadused - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. kahjuritõrjemeetodi, vitoolooli teise olulise osakaalu võib ka vähendada kui kaudset mõju. samuti vähenevad agressiivsed ja seksuaalsed (paigaldus) käitumised. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).
nespo
dompé biotec s.p.a. - darbepoetiin alfa - kidney failure, chronic; anemia; cancer - antianemilised preparaadid - kroonilise neerupuudulikkusega (crf) seotud sümptomaatilise aneemia ravi täiskasvanutel ja lastel. ravi on sümptomaatiline aneemia täiskasvanud vähiga patsientidel, kellel on mitte-müeloidne malignancies saanud keemiaravi.
morphasol süstelahus
animedica gmbh - butorfanool - süstelahus - 4mg 1ml 10ml 1tk; 4mg 1ml 10ml 5tk
repose vet süstelahus
le vet. beheer b.v. - pentobarbitaal - süstelahus - 455,7mg 1ml 250ml 12tk; 455,7mg 1ml 100ml 12tk; 455,7mg 1ml 100ml 1tk
raploc infusioonilahuse pulber
amomed pharma gmbh - landiolool - infusioonilahuse pulber - 300mg 1tk
esmocard lyo infusioonilahuse kontsentraadi pulber
orpha-devel handels und vertriebs gmbh - esmolool - infusioonilahuse kontsentraadi pulber - 2500mg 1viaal
pexion
boehringer ingelheim vetmedica gmbh - imepitoiin - muud antiepileptics, antiepileptics - koerad - koerte idiopaatilise epilepsiaga kaasnevate generaliseerunud krambide sageduse vähendamiseks pärast alternatiivsete ravivõimaluste hoolikat hindamist.
tygacil
pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibacterials süsteemseks kasutamiseks, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid. vajadusele kasutada antibakteriaalseid aineid.
roctavian
biomarin international limited - valoctocogene roxaparvovec - antihemorraagilised ained - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).